Published in Qual Life Res on January 13, 2012
Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention | NCT04923880
Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis. Springerplus (2016) 1.45
Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest (2013) 0.85
Nutritional status is associated with health-related quality of life in children with cystic fibrosis aged 9-19 years. J Cyst Fibros (2013) 0.81
Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches. Health Qual Life Outcomes (2015) 0.75
Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. J Cyst Fibros (2015) 0.75
Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Prefer Adherence (2017) 0.75
Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up. Eur J Pediatr (2017) 0.75
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr (2007) 3.49
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA (2005) 2.56
Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest (2003) 2.54
Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum (2007) 2.27
Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.03
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med (2002) 1.88
The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol (2002) 1.85
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol (2010) 1.71
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.70
Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA (2010) 1.69
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol (2002) 1.67
Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol (2007) 1.67
Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol (2004) 1.65
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol (2004) 1.64
Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med (2006) 1.63
Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr (2008) 1.60
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
An improved powered ankle-foot orthosis using proportional myoelectric control. Gait Posture (2005) 1.56
Mechanical performance of artificial pneumatic muscles to power an ankle-foot orthosis. J Biomech (2005) 1.54
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52
Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc (2007) 1.49
Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest (2007) 1.47
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol (2007) 1.46
Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction. Stroke (2006) 1.44
Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum (2004) 1.41
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig (2008) 1.40
A framework for modelling fertility motivation in couples. Popul Stud (Camb) (2004) 1.39
Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol (2008) 1.39
Barriers to anti-inflammatory medication use in childhood asthma. Ambul Pediatr (2003) 1.35
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril (2010) 1.34
Human medial gastrocnemius force-velocity behavior shifts with locomotion speed and gait. Proc Natl Acad Sci U S A (2012) 1.33
The impact of the parental illness representation on disease management in childhood asthma. Nurs Res (2007) 1.33
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr (2009) 1.31
Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol (2008) 1.30
The mechanics and energetics of human walking and running: a joint level perspective. J R Soc Interface (2011) 1.29
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med (2007) 1.29
Symptom perception in childhood asthma: how accurate are children and their parents? J Asthma (2003) 1.28
Parental perceptions of their child's asthma: management and medication use. J Pediatr Health Care (2003) 1.27
Don't ask, don't tell: parental nondisclosure of complementary and alternative medicine and over-the-counter medication use in children's asthma management. J Pediatr Health Care (2008) 1.27
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother (2011) 1.26
Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. J Urol (2003) 1.25
Powered lower limb orthoses for gait rehabilitation. Top Spinal Cord Inj Rehabil (2005) 1.25
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol (2010) 1.23
Cystic fibrosis and transition to adult medical care. Pediatrics (2010) 1.21
Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res (2011) 1.21
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol (2007) 1.19
Efficacy of osteopathic manipulation as an adjunctive treatment for hospitalized patients with pneumonia: a randomized controlled trial. Osteopath Med Prim Care (2010) 1.19
Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol (2012) 1.14
Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Ann Am Thorac Soc (2014) 1.13
A PHYSIOLOGIST'S PERSPECTIVE ON ROBOTIC EXOSKELETONS FOR HUMAN LOCOMOTION. Int J HR (2007) 1.13
Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest (2009) 1.11
Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol (2004) 1.09
Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med (2002) 1.08
Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol (2011) 1.06
Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol (2003) 1.06
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros (2014) 1.06
An exoskeleton using controlled energy storage and release to aid ankle propulsion. IEEE Int Conf Rehabil Robot (2011) 1.05
Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. Ann Allergy Asthma Immunol (2002) 1.04
Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol (2004) 1.04
Estimation of quasi-stiffness and propulsive work of the human ankle in the stance phase of walking. PLoS One (2013) 1.04
Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther (2007) 1.04
Complementary and alternative medicine use in children with asthma: prevalence and sociodemographic profile of users. J Asthma (2007) 1.03
A pipeline of therapies for cystic fibrosis. Semin Respir Crit Care Med (2009) 1.03
Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros (2013) 1.00
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol (2005) 1.00
The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol (2005) 1.00
Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol (2010) 1.00
Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros (2010) 1.00
Elastic ankle exoskeletons reduce soleus muscle force but not work in human hopping. J Appl Physiol (1985) (2013) 0.99
Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr (2011) 0.99
Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatr Pulmonol (2010) 0.99
Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy. J Oncol Pract (2009) 0.98